# A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet

> **NCT07374224** · PHASE1 · RECRUITING · sponsor: **Guangzhou Lupeng Pharmaceutical Company LTD.** · enrollment: 28 (estimated)

## Conditions studied

- Clinical Pharmacology

## Interventions

- **DRUG:** Rocbrutinib tablets
- **DRUG:** Itraconazole capsules
- **DRUG:** Rifampicin capsules

## Key facts

- **NCT ID:** NCT07374224
- **Lead sponsor:** Guangzhou Lupeng Pharmaceutical Company LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-05
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-08-30
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07374224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07374224, "A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07374224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*